�ٺ���Ƶ

People with opioid use disorder (OUD) receiving treatment with opioid agonists (medications such as methadone or buprenorphine) had an 80 percent lower risk of dying from an opioid overdose compared with people in treatment without the use of medications.

The new findings, , are a collaboration between researchers at NYU Grossman School of Medicine, Johns Hopkins Bloomberg School of Public Health, the Maryland Department of Health, and multiple Maryland State agencies.

The majority of research examining the effectiveness of medication treatment for OUD in population-based studies has been conducted outside of the United States and compares people receiving treatment with those receiving no treatment.

This is one of the first U.S. population-based studies, the researchers say, to compare overdose risk among two patient populations across an entire state—one whose treatment includes agonist medications and a control group receiving psychosocial interventions without agonist medication.

The team of researchers additionally found that being in any kind of treatment for OUD (with or without medication) is protective against overdose compared with not being in treatment at all. However, neither treatment type offers any additional protections against lethal overdose once people leave treatment.

Nationally, approximately 60 percent of people entering specialty treatment for OUD do not receive medication, and many people with access to medication treatment prematurely discontinue care. This is often due to persisting stigma around the use of medication to treat OUD along with logistical barriers involved in accessing medication treatment, which can, in turn, lead to relapse and overdose.

The researchers also found that taking medication while in treatment offered no protection against fatal opioid overdose once people left treatment. “This lack of post-treatment protection highlights the need to promote better retention strategies so that patients can remain in treatment as long as it continues to help them,” says lead study author , assistant professor in the and member of the at �ٺ���Ƶ Health.

They also found that overdose risk was highest in the first month after leaving treatment, for both medication and non-medication treatment groups.

How the Study Was Conducted

Dr. Krawczyk and colleagues examined administrative claims records for publicly funded outpatient specialty treatment programs in 2015 to 2016 for 48,274 patients with primary diagnosis of OUD. The research team then linked these claims to mortality data provided from Maryland’s Office of the Chief Medical Examiner. Seventy-two percent of the people in treatment received medication during the study period, while 28 percent did not (a breakdown that differs significantly from the national landscape, where less than 40 percent of people in treatment receive medication for OUD).

Accounting for time, the researchers compared four distinct groups: people receiving non-medication treatment, people receiving treatment with medication, people no longer in treatment but who left non-medication treatment, and people who left medication treatment.

“Getting people in the door and started on medication treatment is a great first step, but retention in treatment is equally important,” says Dr. Krawczyk. “Because of this, we need to remove barriers to continuation of care, adopt more harm reduction approaches, and employ better strategies to encourage and enable people to stay in treatment.”

Study Limitations

Dr. Krawczyk and colleagues identify a number of study limitations. Findings relied on administrative data used for payment and not research, which limits clinical information available. The investigators also clustered all types of non-medication treatment together and were unable, for example, to distinguish between specific non-medication treatment types such as counseling relative to detox. Similarly, they grouped buprenorphine and methadone together; they did not compare patients using different opioid agonists. Finally, the study focuses only on people receiving outpatient specialty treatment and does assess overdose risk among people receiving buprenorphine in primary care settings.

In addition to Dr. Krawczyk, study co-authors from Johns Hopkins Bloomberg School of Public Health Public and Johns Hopkins School of Medicine were Ramin Mojtabai, PhD; Elizabeth Stuart, PhD; Michael Fingerhood, MD; Deborah Agus, JD; Jonathan Weiner, DrPH; and Brendan Saloner, PhD. The co-author from the Maryland Department of Health was Casey Lyons, MPH.

Funding for the study was supported by grant number 2015-PM-BX-K002 awarded to the Maryland Department of Health by the Bureau of Justice Assistance of the U.S. Department of Justice. This research was also supported by the National Institute on Drug Abuse (grant F31DA047021 awarded to Dr. Krawczyk).

Media Inquiries

Sasha Walek
Phone: 646-501-3873
sasha.walek@nyulangone.org